Surgery, with as wide a margin of removal as possible, has generally been the most effective and preferred way to attack<unk> . If surgical margins are narrow or not clear of tumor, however, or in some situations where tumor cells were left behind, chemotherapy or radiation has been shown to give a clear survival benefit. While<unk>  tends to be resistant to radiation and chemotherapy, each case is different and results can vary widely. For metastatic (widespread) disease, chemotherapy and targeted therapies are the first choices. Chemotherapy regimens are include: doxorubicin/ ifosfamide and doxorubicin combination/gemcitabine and docetaxel/ trabectedin; pazopanib is the targeted therapy used in metastatic<unk>  as second line and is well tolerated.<unk>  of uterine origin often responds to hormonal treatments. As of 2020, several clinical trials for uterine<unk>  are active.
Leiomyosarcoma
Uterine fibroid  s  1
Uterine sarcoma
Adenomyoma
Endometrial stromal sarcoma
Endometrial stromal tumour
Piloleiomyoma
Uterine adenosarcoma